ArticleFolia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP)2026
Short-Term Evaluation of the APrevent® VOIS Implant: Outcomes at 7 Weeks Post-Implantation.
Article in Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Three-dimensional planning to optimize individual implant shape and location in thyroplasty surgery: How I do it.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Type I medialization thyroplasty (MT) is one of the standard procedures in patients having permanent unilateral vocal fold paralysis (UVFP) with insufficient glottal closure. The objective of this study was to evaluate the clinical outcome in patients with UVFP 7 weeks post-implantation using the novel APrevent® VOIS (VOIS) implant with its adjustable balloon.
methodsThe VOIS implant was applied in 32 patients with UVFP during MT. The following parameters were assessed pre- and 7 weeks post-implantation: glottal closure according to Södersten and Lindestad classification (videolaryngostroboscopy), perceptual voice assessment (GRBAS scores), acoustic voice parameters (jitter %, shimmer Db, and harmonic to noise ratio [HNR in dB]), maximum phonation time (MPT in s), voice range profile (VRP), as well as the subjective voice rating of patients (voice handicap index [VHI-30]).
resultsSignificant improvement in glottal closure was achieved in 28 patients (87.5%) 7 weeks after MT with VOIS implant. Adjustment via emptying and refilling of the incorporated balloon of the implant was necessary in 5 patients to further improve or restore the glottal closure. The mean GRBAS scores improved from preoperatively G
conclusionThe novel VOIS implant can be applied safely in patients with UVFP. Patients can further benefit from the intra- and postoperative adjustment, especially that of the posterior glottal closure using the custom-fitting option by re-filling the balloon of the implant. To better evaluate the sustainability of the VOIS implant in terms of safety and effectiveness for patients with UFVP, it is crucial to conduct further analysis of long-term outcomes post-implantation in future studies. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.